Literature DB >> 1457272

Effect of alacepril on blood pressure and neurohumoral factors at rest and during dynamic exercise in patients with essential hypertension.

T Kinugawa1, H Kitamura, K Ogino, N Noguchi, T Matsumoto, I Hisatome, H Miyakoda, H Kotake, H Mashiba.   

Abstract

We assessed blood pressure and neurohumoral factors at rest and during exercise in 10 patients with essential hypertension before and after treatment with the new angiotensin converting enzyme inhibitor, alacepril (25-50 mg day-1). Alacepril significantly lowered mean blood pressure at rest and at the same exercise load as before treatment without affecting heart rate response. The response of plasma renin activity, plasma aldosterone, and plasma adrenaline were not changed by alacepril, but increase of plasma angiotensin II and plasma noradrenaline during exercise were significantly attenuated after alacepril treatment (ANOVA, P = 0.04, both). The change in mean blood pressure during exercise was positively correlated with the decrease in plasma angiotensin II (r = 0.65, P < 0.05). These results demonstrated that alacepril was effective in essential hypertension both at rest and during exercise, suggesting that the antihypertensive effect during exercise might be related to the decrease in pressor hormones, especially in plasma angiotensin II.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1457272      PMCID: PMC1381422          DOI: 10.1111/j.1365-2125.1992.tb05922.x

Source DB:  PubMed          Journal:  Br J Clin Pharmacol        ISSN: 0306-5251            Impact factor:   4.335


  15 in total

1.  A non-chromatographic non-extraction radioimmunoassay for serum aldosterone.

Authors:  T Ogihara; K Iinuma; K Nishi; Y Arakawa; A Takagi
Journal:  J Clin Endocrinol Metab       Date:  1977-10       Impact factor: 5.958

Review 2.  Sympathetic nervous system during converting enzyme inhibition.

Authors:  I G Crozier; R Teoh; R Kay; M G Nicholls
Journal:  Am J Med       Date:  1989-12-26       Impact factor: 4.965

3.  Action of angiotensin on adrenergic nerve endings: enhancement of norepinephrine biosynthesis.

Authors:  R H Roth
Journal:  Fed Proc       Date:  1972 Jul-Aug

4.  Action of angiotensin on vascular adrenergic nerve endings: facilitation of norepinephrine release.

Authors:  B G Zimmerman; S K Gomer; J C Liao
Journal:  Fed Proc       Date:  1972 Jul-Aug

5.  Action of angiotensin on adrenergic nerve endings: inhibition of norepinephrine uptake.

Authors:  P A Khairallah
Journal:  Fed Proc       Date:  1972 Jul-Aug

6.  Liquid-chromatographic determination of norepinephrine and epinephrine in human plasma.

Authors:  Y Yui; T Fujita; T Yamamoto; Y Itokawa; C Kawai
Journal:  Clin Chem       Date:  1980-02       Impact factor: 8.327

7.  Sympathetic nervous activity and noradrenaline reactivity during angiotensin converting enzyme inhibition.

Authors:  T Philipp; A M Sharma; H M Thiede; A Kribben
Journal:  Am J Cardiol       Date:  1987-04-24       Impact factor: 2.778

8.  Effects of enalapril maleate on blood pressure, renin-angiotensin-aldosterone system, and peripheral sympathetic activity in essential hypertension.

Authors:  G Cerasola; S Cottone; G D'Ignoto; L Grasso; M B Carone; E Carapelle; A Contorno
Journal:  Clin Ther       Date:  1987       Impact factor: 3.393

9.  Antihypertensive activity of alacepril in spontaneously hypertensive rats and deoxycorticosterone acetate-salt hypertensive rats and dogs.

Authors:  K Takeyama; H Minato; F Fukuya; S Kawahara; K Hosoki; T Kadokawa
Journal:  Arzneimittelforschung       Date:  1985

10.  Disposition and metabolism of the novel antihypertensive agent alacepril in rats.

Authors:  K Matsumoto; H Miyazaki; T Fujii; K Yoshida; H Amejima; M Hashimoto
Journal:  Arzneimittelforschung       Date:  1986
View more
  1 in total

1.  Effects of ACE inhibition on endurance exercise haemodynamics in trained subjects with mild hypertension.

Authors:  P Palatini; S Bongiovi; L Mario; P Mormino; G Raule; A C Pessina
Journal:  Eur J Clin Pharmacol       Date:  1995       Impact factor: 2.953

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.